Cancer upregulated gene 2, a novel oncogene, enhances migration and drug resistance of colon cancer cells via STAT1 activation

International Journal of Oncology

Volumn 43, Issue 4, 2013, Pages 1111-1116

  Malilas, Waraporn ^a   Koh, Sang Seok ^b   Kim, Seokho ^b   Srisuttee, Ratakorn ^a   Cho, Il Rae ^a   Moon, Jeong ^a   Yoo, Hwa Seung ^c   Oh, Sangtaek ^d   Johnston, Randal N ^e   Chung, Young Hwa ^a  

^a Pusan National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Daejeon University   (South Korea)

^d Kookmin University   (South Korea)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cancer upregulated gene 2; Cell migration; Drug resistance; STAT1

Indexed keywords

DOXORUBICIN; JANUS KINASE 1; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; STAT1 PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER UPREGULATED GENE 2; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; ENZYME INHIBITION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WOUND HEALING;

APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM METASTASIS; NUCLEAR PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; WOUND HEALING;

EID: 84882377114     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2049     Document Type: Article

References (32)

1. Lee S, Gang J, Jeon SB, et al: Molecular cloning and functional analysis of a novel oncogene, cancer-upregulated gene 2 (CUG2). Biochem Biophys Res Commun 360: 633-639, 2007.
2. Kim H, Lee M, Lee S, et al: Cancer-upregulated gene 2 (CUG2), a new component of centromere complex, is required for kinetochore function. Mol Cells 27: 697-701, 2009.
3. Park EH, Park EH, Cho IR, et al: CUG2, a novel oncogene confers reoviral replication through Ras and p38 signaling pathway. Cancer Gene Ther 17: 307-314, 2010.
4. Malilas W, Koh SS, Srisuttee R, et al: Cancer upregulated gene 2, a novel oncogene, confers resistance to oncolytic vesicular stomatitis virus through STAT1-OASL2 signaling. Cancer Gene Ther 20: 125-132, 2013.
5. Chin YE, Kitagawa M, Kuida K, Flavell RA and Fu XY: Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol 17: 5328-5337, 1997.
6. Kumar A, Commane M, Flickinger TW, Horvath CM and Stark GR: Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 278: 1630-1632, 1997.
7. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y and Fu XY: Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 272: 719-722, 1996.
8. Townsend PA, Scarabelli TM, Davidson SM, Knight RA, Latchman DS and Stephanou A: STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem 279: 5811-5820, 2004.
9. Stephanou A, Brar BK, Knight RA and Latchman DS: Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ 7: 329-330, 2000.
10. Khodarev NN, Beckett M, Labay E, Darga T, Roizman B and Weichselbaum RR: STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci USA 101: 1714-1719, 2004.
11. Fryknas M, Dhar S, Oberg F, et al: STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines. Int J Cancer 120: 189-195, 2007.
12. Roberts D, Schick J, Conway S, et al: Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer 92: 1149-1158, 2005.
13. Weichselbaum RR, Ishwaran H, Yoon T, et al: An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci USA 105: 18490-18495, 2008.
14. Park HD, Lee Y, Oh YK, et al: Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation. Oncogene 30: 201-211, 2011.
15. Liang CC, Park AY and Guan JL: In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2: 329-333, 2007.
16. Raven JF, Williams V, Wang S, et al: Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. Cell Cycle 10: 794-804, 2011.
17. Kaplan DH, Shankaran V, Dighe AS, et al: Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95: 7556-7561, 1998.
18. Wang S and Koromilas AE: Stat1 is an inhibitor of Ras-MAPK signaling and Rho small GTPase expression with implications in the transcriptional signature of Ras transformed cells. Cell Cycle 8: 2070-2079, 2009.
19. Wang S, Raven JF, Durbin JE and Koromilas AE: Stat1 phosphorylation determines Ras oncogenicity by regulating p27 kip1. PLoS One 3: e3476, 2008.
20. Khodarev NN, Roach P, Pitroda SP, et al: STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS One 4: e5821, 2009.
21. Rickardson L, Fryknas M, Dhar S, et al: Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer 93: 483-492, 2005.
22. Pitroda SP, Wakim BT, Sood RF, et al: STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect. BMC Med 7: 68, 2009.
23. Chun Y, Park B, Koh W, et al: New centromeric component CENP-W is an RNA-associated nuclear matrix protein that interacts with nucleophosmin/B23 protein. J Biol Chem 286: 42758-42769, 2011.
24. Okuwaki M: The structure and functions of NPM1/Nucleophsmin/B23, a multifunctional nucleolar acidic protein. J Biochem 143: 441-448, 2008.
25. Grisendi S, Mecucci C, Falini B and Pandolfi PP: Nucleophosmin and cancer. Nat Rev Cancer 6: 493-505, 2006.
26. Khodarev NN, Roizman B and Weichselbaum RR: Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth. Clin Cancer Res 18: 3015-3021, 2012.
27. Velasco-Velazquez M, Jiao X, De La Fuente M, et al: CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res 72: 3839-3850, 2012.
28. Kitamura T, Fujishita T, Loetscher P, et al: Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model. Proc Natl Acad Sci USA 107: 13063-13068, 2010.
29. Lee JH, Kim HN, Kim KO, et al: CXCL10 promotes osteolytic bone metastasis by enhancing cancer outgrowth and osteoclastogenesis. Cancer Res 72: 3175-3186, 2012.
30. Nakano M, Fujii T, Hashimoto M, et al: Type I interferon induces CX3CL1 (fractalkine) and CCL5 (RANTES) production in human pulmonary vascular endothelial cells. Clin Exp Immunol 170: 94-100, 2012.
31. Nardi V, Naveiras O, Azam M and Daley GQ: ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines. Blood 113: 3813-3820, 2009.
32. Ohmori Y and Hamilton TA: Cooperative interaction between interferon (IFN) stimulus response element and kappaB sequence motifs controls IFN gamma-and lipopolysaccharide-stimulated transcription from the murine IP-10 promoter. J Biol Chem 268: 6677-6688, 1993.